Prostate cancer genetic testing prognosis risk assessment system (Prostatype® te
Prostate cancer genetic testing prognosis risk assessment system (Prostatype® testing system)
BackHomeProductsTumor Detection

Prostate cancer genetic t♥‌esting prognosis risk asses  sment system (Prostatype® testing system)

The world's leading
A global leader: Precision medical findings fr§βom the Nobel institution urologβ ‌y professor at the Karolinska InstΩδ•αitute team for nearly 20 years
1. The global leader in genetic testing for pro☆≈βstate cancer prognostic risk assessment s↑≤←ystem
2. Use the world's only course of treatment a<♥s a real patient Reference risk assessment syst®‍em
3. Research and development achie•αvements of academicians of the Royal Swedish A♠σ"cademy of Engineering (IVA)
4. Combined genetic testing facto←ε​∑rs significantly improve the ¥ accuracy of prognostic scores
5. Revolutionarily provide more sciλ'entific treatment options for patients with pr​≤ostate cancer

Prostate cancer clinical background
1. Prostate cancer is one of the highes✘>σ≠t incidence of male cancer‌ε← in Western developed countries in E™←urope, America and Europe;&ε₩nbsp;
2. With the improvement of economic level and re©§☆✔sidents' living standards in Ch< ↔ina, its incidence rate is al↔πso rapidly increasing. It is expected that it 㱩©will enter Chinese males within ten yea±"rs The top three of malignant tumors;
3. Although the incidence of prostate cancer is h≠←★igh, not all cancer subtypes are m£↔alignant and fatal, and most prostate cancer sδ®♣©ubtypes (nearly 80%) are relatively b"©‌enign rather than fatal;
4. Studies have shown that 7 out ofα∞ 10 of them are over-treated or unde‌≈r-treated, mainly due to the↔'♥✔ low accuracy of clinical prognostic scor₽¥es.
5. The survival rate of p♦☆©♣rostate cancer patients in developed c&≤©ountries is more thaδ≈≠n 98% over 5 years, while in C"¥•σhina Terrible 50%.
Prostate cancer treatment in th§↔e world
Prostatype®

Our prostate cancer risk prog¶α☆nosis detection system
How does it improve forecast accuracy?
What clinical problems can be solve→←☆d?


Testing process
Product advantages
1. The key technology invo€$≠₩lved in this project has applie£♦♦d for an international inventi→β♠‍on patent, which has been approved↑"☆ in Sweden, Japan, China and↑λ♣ the United States.
2. Using the combination ±€≤of the world's leading genetic technology and≈σ biological big data, revoluti↔♥©onaryly provide accurate personalized treat☆δσ★ment programs for prostate patients, and$±±↔ greatly improve the accuracy of patient progno₽★sis risk assessment.
3. This project is based on the advantagו★es of Sweden's first and the most coφ<×mplete clinical samples an☆σd follow-up data in the world, and complet♥™∑ely tracks the patient's entire pr♣>​≠ocess.
4. The database of this project is composed of 60Ω♠✘'0 real cases, and the patient's clinical data a♣ ≥★nd genetic test data are completely collected.​★ The software that meets the clinical regis×∑₩tration standards was developed using &♣§φmathematical models and statistiγ₩ ↕cal analysis. The software's prostate cancδ♦'er risk classification The algorithm   and cancer risk index are globally unique and™"  have passed CE certification.
5. This project is currentl¶←π☆y the only testing system in the world tha Ω♥t does not need to send patient samples to≈★ a special laboratory for ¥ §←testing, and can be directly used iβ✘$₹n the clinic for doctors •✔★★to use.
6. Prostatype can improve∑π₹ε the accuracy of prognosis judgment of survival t≥§ime by 25%, especially ★↕$↓for patients with medium-risk patients wφ©λγho are most difficultα≈≥ to choose treatment options.
Prognostic system compared with Europea♥'n standards EAU and CARPA
Comparison of international mainstream prod®↓<ucts

Company name

Chundsell Medicals (Swed♥λ←en)

Genomic Health (United States)

Myriad GeneDcs (United States)

MetamarksGeneDcs (United States)

Bostwick Laborator

ies (United States)

product name

Prostatype®Test System↓±γ®

Oncotype Prostate DX

Prolaris

Promark

ProstaVysion

Detection gene

RNA expression levels of 4 related<♦ genes

17 related gene RNA expression♦↓ levels

46 related gene RNA expression £ε‍φlevels

8 related protein expreα∑∑✔ssion levels

3 related gene mutat★£ions

Gene type

Stem cell gene

Proliferation gene

Proliferation gene

Proliferation gene

Proliferation gene

Clinical application

Treatment and survival prognosis

Prognosis of treatment¥↔, refer to NCNN

Treatment prognosis, refer to CAPRA

Prognosis of treatment, refe✔‌↓÷r to NCNN

No

Scientific verification

3 articles

2 articles

2 articles

3 articles

PTEN / ERG related reports

Laboratory type

Local molecular pathology experiment

CLIA Standardized Laboratory

CLIA Standardized Laboratory

CLIA Standardized Laboratory

CLIA Standardized Laboratory

Forecast period

2 days

7 days

7 days

7 days

7 days

Applied country

Sweden, Switzerland, Germanyσ≈>

United States, Germany, Switzerlan←$§φd

United States, Germany, Switzerland

United States

United States







Prognosis evaluation system s&♦←¥ervice object
For the patient
1. Provide information for thφ↑®∑e patient before deciding whether t✔₩πo treat
2. Help the patient to participate in the form✘↔וulation

For the urologist
1. Provide a more accurate treatment plan
2. Avoid overtreatment ☆•or undertreatment
3. Discuss the treatment plan f ±↔or the patient Provide strong÷≈∏  support

For pathologists
1. Balance the subje≠♥Ω®ctivity of Gleason Index
2. Enhance pathological assessment in☆¥≥formation

Product Category
Latest News